Even though pathological markers (ER, PR and HER2) can be used to differentiate between LumA and LumB breast cancers, and these markers are routinely used clinically to stratify patients for prediction and treatment selection, a pre‐clinical approach to differentiate between these two types and for subsequent treatment selection is lacking. The gene discussed is ERBB2; the disease is breast cancer.